Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONSOLIDATED BALANCE SHEETS

v3.3.0.814
UNAUDITED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2015
Dec. 31, 2014
Current assets    
Cash $ 16,913 $ 623
Total current assets 16,913 623
Fixed assets - net 41 454
Total Assets 16,954 1,077
Current liabilities    
Accounts payable 623,839 484,260
Accrued interest payable 535,387 407,684
Notes payable - current - related parties 697,225 697,225
Notes payable - current, net 879,669 871,694
Notes payable - derivitive liability payable 0 25,456
Stock subscription payable 28,067 28,067
Related party payables 385,765 296,265
Other payables 241,915 241,922
Total current liabilities 3,391,867 3,052,573
Long-Term Liabilities    
Notes payable - related parties, net of current portions 43,298 43,298
Total Liabilities 3,435,165 3,095,871
Stockholders' Deficit    
Common stock, $.00001 par value; 100,000,000 shares authorized; 60,251,068 and 58,416,660 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively 602 585
Additional paid in capital 12,773,244 12,716,630
Accumulated deficit (16,153,777) (15,777,222)
Total Transbiotec, Inc. stockholders' deficit (3,379,931) (3,060,007)
Noncontrolling interest (38,280) (34,787)
Total Stockholders' Deficit (3,418,211) (3,094,794)
Total Liabilities and Stockholders' Deficit $ 16,954 $ 1,077